Special Issue "Towards Host-Centric Antivirals"
Deadline for manuscript submissions: 30 November 2021.
Interests: host-centric antivirals; influenza A virus; coronavirus, SARS-CoV-2; respiratory syncytial virus; innate immunity; virus–host interactions; host resistance to viral infection
Interests: antiviral; influenza A virus; African swine fever virus; innate immunity; virus–host interactions; host-centric antivirals; antiviral resistance; drug repurposing
The aim of this Special Issue is to promote the research and development of host-based antivirals as an alternative approach to virus-based antiviral targeting.
Ninety antiviral drugs have been approved for the treatment of only nine human diseases, highlighting the challenges of antiviral development. Targeting viral proteins through direct-acting antivirals has been, and remains, the primary strategy employed. However, the emergence of antiviral resistance is a significant challenge, particularly for highly mutable RNA viruses such as influenza A viruses. An alternative strategy is to exploit the absolute dependency of viruses on host cells for their replication by targeting host processes or factors, either inhibiting pro-viral host factors or inducing antiviral host-innate immune responses. A further advantage of this strategy is its potential broad-spectrum antiviral activity against related (RNA) viruses. The development of broad-spectrum antivirals which can be used to treat emergent viruses is clearly advantageous, as exemplified by the current pandemic. Even in the presence of effective vaccines, antivirals for treatment and prophylaxis are essential in managing active viral infections. Furthermore, understanding the mechanism of action of particular host-centric antivirals could further refine our understanding of host–virus interactions.
We invite all researchers working in the field of antiviral development to submit original research papers, short communications or reviews to this Special Issue of Viruses to highlight recent advances and further the discussion on host-centric therapeutics.
Prof. Dr. Kin-Chow Chang
Dr. Leah Goulding
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- virus–host interactions